Information-Rich Drug Discovery Enabled by Next-Generation Multiplexing SPR

Detailed validation is key in successful drug development. Surface plasmon resonance (SPR) offers a label-free, direct-binding analysis that brings additional insights into drug kinetics compared to established functional assays.

SPR gives detailed information on affinity, complex half-life, thermodynamic constants and mode-of-action of potential candidates.

In this webinar, you’ll discover how SPR can be multiplexed and automated to enable high-throughput, data-rich drug candidate screening against multiple target proteins.

Attend this webinar to discover:

• The relevance of kinetics and SPR for your drug development project
• The value of multiplexing assays for drug development
• Bruker’s newest Triceratops SPR #64, its flexibility and throughput in drug discovery and development pipelines

Presenter: Dr. Cyrill George Brunner (Senior Application Specialist, Bruker Daltonics)